• Intratumoral Cancer Therapies Market Predicted to See Upsurge openPR.com Tue, 29 Apr 2025 20:34:00 GMT
• metastatic melanoma clinical trials and studies 2025: ema, pdma, fda approvals, mechanism of action, roa, nda, ind, and companies The Globe and Mail Fri, 11 Apr 2025 00:02:00 GMT
• tcehy earnings: tencent profits leap on gaming and ads as investors wait on ai returns The Globe and Mail Wed, 19 Mar 2025 07:00:00 GMT
• 3 dividend stocks to buy for reliable passive income The Globe and Mail Wed, 19 Mar 2025 07:00:00 GMT
• ratio chart of u.s. dollar index against 10y u.s. notes is pointing much lower The Globe and Mail Thu, 06 Mar 2025 03:02:49 GMT
• ratio chart of u.s. dollar index against 10y u.s. notes is pointing much lower The Globe and Mail Wed, 05 Mar 2025 08:00:00 GMT
• zoom stock: leading the video market after skype’s exit The Globe and Mail Tue, 04 Mar 2025 08:00:00 GMT
• 3 reasons to avoid sgh and 1 stock to buy instead The Globe and Mail Fri, 21 Feb 2025 08:00:00 GMT
• new york’s mta further electrifies fleet, with order for 265 battery-electric buses from nfi subsidiary new flyer The Globe and Mail Fri, 14 Feb 2025 08:00:00 GMT
• cytokinetics names robert e. landry to board of directors The Manila Times Tue, 11 Feb 2025 08:00:00 GMT
• regeneron's growth architect joins cytokinetics (cytk) board as company nears historic first drug launch Stock Titan Tue, 11 Feb 2025 08:00:00 GMT
• Intratumoral Cancer Therapies Market Size to Reach USD 323.9 Billion by 2035, Impelled by Advancements in Early Detection BioSpace Fri, 31 Jan 2025 08:00:00 GMT
• bristol myers, pfizer tout new standards of care in colorectal cancer subtypes FiercePharma Sat, 25 Jan 2025 08:00:00 GMT
• u.s. food and drug administration approves opdivo qvantig™ (nivolumab and hyaluronidase-nvhy) injection, for subcutaneous use in m... Bristol Myers Squibb - News Fri, 27 Dec 2024 08:00:00 GMT
• head and neck cancer diagnostics market growth, trends, size, share, forecast to 2033 WhaTech Wed, 04 Dec 2024 08:00:00 GMT
• checkpoint inhibitor refractory cancer market to reach new heights in growth by 2032, delveinsight predicts | checkmate pharma, bi... Barchart Tue, 26 Nov 2024 08:00:00 GMT
• 2 penny stocks that wall street predicts will soar 306% to 1,183% in 2025 The Globe and Mail Mon, 25 Nov 2024 08:00:00 GMT
• pd-1 and pd-l1 inhibitors market projected to surge, reaching usd xx billion by 2031 as revealed in new report WhaTech Wed, 13 Nov 2024 09:35:32 GMT
• did viking therapeutics just say "checkmate" to eli lilly? The Motley Fool Wed, 13 Nov 2024 08:00:00 GMT
• legend names a president of carvykti; novo nordisk's top north america exec is stepping down Endpoints News Fri, 08 Nov 2024 08:00:00 GMT
• legend biotech names alan bash as leader of its car-t product ROI-NJ.com Tue, 05 Nov 2024 17:52:17 GMT
• legend biotech appoints alan bash as president of carvykti® StockTitan Mon, 04 Nov 2024 08:00:00 GMT
• immunotherapy combination may demonstrate benefit in patients with cutaneous melanoma The ASCO Post Mon, 04 Nov 2024 08:00:00 GMT
• combination therapy shows promising results in treating stage 3 melanoma News-Medical.Net Fri, 01 Nov 2024 07:00:00 GMT
• axonis therapeutics announces $115 million series a financing Nasdaq Wed, 30 Oct 2024 10:00:00 GMT
• intratumoral cancer therapies market size, growth opportunities, trends by 2033 WhaTech Thu, 19 Sep 2024 12:29:41 GMT
• intratumoral cancer therapies market key drivers, insights, outlook, overview and market research report 20... WhaTech Wed, 18 Sep 2024 07:12:41 GMT
• pd-1 and pd-l1 inhibitors market set to surge, reaching usd xx billion by 2031 WhaTech Fri, 09 Aug 2024 07:00:00 GMT
• pd-1 inhibitors market: driving innovation, expanding therapeutic applications, and improving patient survi... WhaTech Sun, 04 Aug 2024 07:00:00 GMT
• venbio raises $528 million venture capital fund focused on life science companies Business Wire Thu, 01 Aug 2024 07:00:00 GMT
• metastatic melanoma pipeline assessment 2024: fda, ema, and pmda approvals, emerging drugs - coin plus ... Coin Plus（コインプラス） Wed, 03 Jul 2024 08:49:51 GMT
• checkpoint inhibitor refractory cancer market size and share analysis Future Market Insights Mon, 01 Jul 2024 15:35:21 GMT
• recurrent or metastatic head and neck cancer pipeline 2024 | fda approvals, clinical trials, therapies, moa, roa ... Barchart Tue, 25 Jun 2024 23:28:42 GMT
• Decheng Capital Eyes $700M Raise for Fifth Life Sciences Fund as VC Heats Up BioSpace Tue, 18 Jun 2024 07:00:00 GMT
• recurrent or metastatic head and neck cancer pipeline outlook report 2024 (updated) openPR Fri, 07 Jun 2024 00:34:00 GMT
• recurrent or metastatic head and neck cancer pipeline outlook report 2024 (updated) openPR Thu, 06 Jun 2024 23:47:07 GMT
• here's why we're watching checkmate pharmaceuticals' (nasdaq:cmpi) cash burn situation Yahoo Movies UK Tue, 04 Jun 2024 17:25:11 GMT
• asco: with opdivo-yervoy combo, bristol myers calls roche and astrazeneca's bets in first-line liver cancer Fierce Pharma Tue, 04 Jun 2024 07:00:00 GMT
• why is checkmate pharmaceuticals (cmpi) stock up 300% today? The Globe and Mail Thu, 23 May 2024 23:10:43 GMT
• we think checkmate pharmaceuticals (nasdaq:cmpi) can afford to drive business growth Yahoo New Zealand News Sun, 19 May 2024 02:49:00 GMT
• as bristol myers reveals trial failure, astrazeneca's imfinzi stays king in stage 3 lung cancer FiercePharma Mon, 13 May 2024 07:00:00 GMT
• bristol myers fails to beat astrazeneca in stage 3 lung cancer FiercePharma Mon, 13 May 2024 07:00:00 GMT
• ers international congress 2016 - vidutolimod, biotechnology The Pharma Letter Tue, 07 May 2024 07:43:46 GMT
• with the buyout of decibel, a once promising local biotech cluster has faded from the scene MSN Mon, 06 May 2024 09:46:03 GMT
• u.s. food and drug administration accepts bristol myers squibb’s application for subcutaneous nivolumab (nivolumab and hyaluronida... Business Wire Mon, 06 May 2024 07:00:00 GMT
• intratumoral cancer therapies market to observe impressive growth during the forecast period (2023-2032 ... openPR Tue, 09 Apr 2024 07:00:00 GMT
• pd-1 and pd-l1 inhibitors market research explores latest report with forecast to 2031 WhaTech Fri, 05 Apr 2024 07:00:00 GMT
• microbiome-targeted therapies can improve cancer outcomes. what oncologists should know about the potential impact of probiotics o... ASCO Daily News Thu, 28 Mar 2024 07:08:55 GMT
• Biotech veteran Art Krieg postpones retirement to build an unorthodox drug startup BioPharma Dive Thu, 28 Mar 2024 07:00:00 GMT
• biotech veteran art krieg postpones retirement to build an unorthodox drug startup Yahoo Finance Wed, 27 Mar 2024 07:00:00 GMT
• after opdivo flop in liver cancer, bristol myers finds yervoy combo could save lives FiercePharma Wed, 20 Mar 2024 07:00:00 GMT
• bms shoots for 1l liver cancer again with opdivo, yervoy combo FiercePharma Wed, 20 Mar 2024 07:00:00 GMT
• microbiome-targeted therapies can improve cancer outcomes. what oncologists should know about the potential impact of probiotics o... ASCO Daily News Wed, 13 Mar 2024 07:00:00 GMT
• hyku biosciences, a covalent precision medicine company, announces ceo transition for its next phase of growth GlobeNewswire Mon, 11 Mar 2024 07:00:00 GMT
• bristol myers, overshadowed by adc rival, wins fda nod for opdivo combo in bladder cancer FiercePharma Fri, 08 Mar 2024 08:00:00 GMT
• pembrolizumab versus placebo as adjuvant therapy in resected stage iib or iic melanoma: final analysis of distant metastasis-free ... ASCO Journals Thu, 07 Mar 2024 08:00:00 GMT
• regeneron forks out $250m to buy checkmate pharmaceuticals BioProcess International Sat, 02 Mar 2024 13:22:00 GMT
• colorectal cancer research from asco gi: immunotherapy, ctdna, and surgery Cancer Therapy Advisor Mon, 05 Feb 2024 08:00:00 GMT
• metastatic melanoma pipeline and clinical trials assessment, 2024 updates: fda approvals, therapies and key co openPR Thu, 01 Feb 2024 19:33:00 GMT
• bristol myers shows power of opdivo-yervoy combo in first-line colorectal cancer subset FiercePharma Sat, 20 Jan 2024 08:00:00 GMT
• Checkpoint Inhibitor Refractory Cancer Industry Targets a Striking US$ 112.43 Billion Milestone by 2033-FMI Study PharmiWeb.com Thu, 21 Dec 2023 08:00:00 GMT
• bms chases msd/seagen with first-line bladder cancer filing pharmaphorum Tue, 05 Dec 2023 17:16:31 GMT
• metastatic melanoma pipeline and clinical trials assessment 2023: fda approvals, therapies and key companies i openPR Tue, 05 Dec 2023 08:00:00 GMT
• what we're reading: affordable home care; mycoplasma infections ... AJMC.com Managed Markets Network Mon, 04 Dec 2023 15:30:21 GMT
• immunitas therapeutics announces appointment of james wooldridge as chief medical officer and upcoming presentation at ash 2023 an... PR Newswire Mon, 04 Dec 2023 08:00:00 GMT
• immunitas therapeutics appoints james wooldridge as chief medical officer citybiz Mon, 04 Dec 2023 08:00:00 GMT
• fda starts review of padcev/keytruda for bladder cancer pharmaphorum Fri, 01 Dec 2023 11:00:35 GMT
• fda grants priority review to frontline enfortumab vedotin plus ... Urology Times Fri, 01 Dec 2023 00:19:09 GMT
• perioperative nivolumab plus chemotherapy improves event-free ... The ASCO Post Thu, 30 Nov 2023 16:15:55 GMT
• pc14586 targets previously “undruggable” p53 in treatment of ... OncLive Mon, 27 Nov 2023 20:22:51 GMT
• two studies show improved survival with novel front-line ... The ASCO Post Sat, 25 Nov 2023 08:00:00 GMT
• selinexor maintenance leads to pfs benefit in tp53 wild-type ... OncLive Wed, 22 Nov 2023 08:00:00 GMT
• a phase ii clinical trial evaluating the safety and efficacy of ... The Lancet Tue, 21 Nov 2023 08:00:00 GMT
• esmo 2023: current research on advanced and progressing ... Cancer Therapy Advisor Fri, 17 Nov 2023 08:00:00 GMT
• geopolitics, rates drag on private equity deals; israel's high pe ... S&P Global Fri, 17 Nov 2023 08:00:00 GMT
• clinicopathologic features and prognostic value of claudin 18.2 ... Nature.com Thu, 16 Nov 2023 08:00:00 GMT
• adcs shine at esmo '23, as pharma makes case for early ... pharmaphorum Tue, 14 Nov 2023 08:00:00 GMT
• evolving treatment patterns and improved outcomes in relapsed ... Nature.com Mon, 13 Nov 2023 08:00:00 GMT
• earnings call: cue biopharma highlights potential of immuno-stat ... Investing.com Nigeria Sun, 12 Nov 2023 12:31:25 GMT
• enfortumab vedotin plus pembrolizumab has potential to alter soc ... OncLive Fri, 10 Nov 2023 08:00:00 GMT
• new approaches show promise for treatment of gastroesophageal ... Healio Wed, 08 Nov 2023 08:00:00 GMT
• jnj: 3 pharma stocks to capitalize on with potential upside StockNews.com Thu, 02 Nov 2023 07:00:00 GMT
• ema validates bms’ opdivo application for bladder cancer Pharmaceutical Technology Mon, 30 Oct 2023 07:00:00 GMT
• frontline nivolumab plus chemotherapy boosts os and pfs in ... OncLive Sun, 22 Oct 2023 07:00:00 GMT
• esmo: in showdown with merck's keytruda, bms' opdivo delivers ... FiercePharma Sat, 21 Oct 2023 07:00:00 GMT
• positive topline results reported from bristol myers squibb's phase 3 checkmate-67t trial of subcutaneous nivolumab with halozyme'... PR Newswire Thu, 19 Oct 2023 07:00:00 GMT
• Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial Nature Mon, 16 Oct 2023 07:00:00 GMT
• (pdf) adjuvant nivolumab in resected stage iib/c melanoma: primary results from the randomized, phase 3 checkmate 76k trial ResearchGate Mon, 16 Oct 2023 07:00:00 GMT
• fda approves adjuvant nivolumab in completely resected stage ... Cancer Network Mon, 16 Oct 2023 07:00:00 GMT
• merck's keytruda hits overall survival goal in early lung cancer as ... FiercePharma Tue, 10 Oct 2023 07:00:00 GMT
• merck eyes new bladder cancer space with positive keytruda trial in ... FiercePharma Thu, 05 Oct 2023 07:00:00 GMT
• bristol myers joins astrazeneca, merck in touting positive lung cancer drug use around surgery Fierce Pharma Fri, 22 Sep 2023 07:00:00 GMT
• latest trial win supports expanded use of bristol myers' opdivo in ... BioPharma Dive Fri, 22 Sep 2023 07:00:00 GMT
• health-related quality of life with nivolumab plus chemotherapy versus chemotherapy in patients with advanced ... ASCO Journals Fri, 15 Sep 2023 07:00:00 GMT
• phase iii trial reports chemoimmunotherapy is superior to ... The ASCO Post Sun, 10 Sep 2023 07:00:00 GMT
• adjuvant nivolumab versus ipilimumab in resected stage iii/iv ... Cancer Discovery Fri, 01 Sep 2023 08:22:16 GMT
• perioperative trials add to growing immunotherapy landscape in ... OncLive Thu, 31 Aug 2023 07:00:00 GMT
• ec approves bristol myers squibb's opdivo for melanoma Pharmaceutical Technology Wed, 23 Aug 2023 07:00:00 GMT
• systemic therapy for melanoma: asco guideline update | journal ... ASCO Journals Mon, 14 Aug 2023 07:00:00 GMT
• Regeneron Buys Decibel’s Hearing Loss Gene Therapies in $109M Deal BioSpace Wed, 09 Aug 2023 07:00:00 GMT
• with the buyout of decibel, a once promising local biotech cluster has faded from the scene The Boston Globe Wed, 09 Aug 2023 07:00:00 GMT
• regeneron reports second quarter 2023 financial and operating ... Yahoo Finance Thu, 03 Aug 2023 07:00:00 GMT
• contribution of mek inhibition to braf/mek inhibitor combination ... ASCO Journals Fri, 28 Jul 2023 07:00:00 GMT
• bristol myers squibb - bristol myers squibb reports second quarter ... Bristol-Myers Squibb Thu, 27 Jul 2023 07:00:00 GMT
• cutaneous melanoma market is predicted to exhibit remarkable growth, predicts delveinsight | key companies ... PR Newswire Mon, 24 Jul 2023 07:00:00 GMT
• autolus therapeutics appoints dolski as cfo, hersberger, neville as svps - tipranks.com TipRanks Thu, 20 Jul 2023 13:58:54 GMT
• bristol myers' opdivo stages comeback in bladder cancer, teeing up ... FiercePharma Tue, 11 Jul 2023 07:00:00 GMT
• debating sentinel lymph node biopsy for melanoma in the modern ... ASCO Journals Thu, 06 Jul 2023 07:00:00 GMT
• phase i trial of pembrolizumab plus vemurafenib and cobimetinib in patients with metastatic melanoma Frontiers Sat, 01 Jul 2023 19:12:22 GMT
• adjuvant pembrolizumab continues to provide survival benefit in ... OncLive Fri, 30 Jun 2023 07:00:00 GMT
• seven-year follow-up of the phase iii keynote-006 study ... ASCO Journals Thu, 22 Jun 2023 07:00:00 GMT
• intracranial efficacy of adagrasib in patients from the krystal-1 ... ASCO Journals Fri, 16 Jun 2023 07:00:00 GMT
• melanoma market to witness promising growth, predicts delveinsight | key companies to watch - io biotech, merck ... PR Newswire Mon, 12 Jun 2023 07:00:00 GMT
• diversifying eligibility to enhance real-world results | journal of ... ASCO Journals Mon, 12 Jun 2023 07:00:00 GMT
• first-line, fixed-duration nivolumab plus ipilimumab followed by ... ASCO Journals Mon, 12 Jun 2023 07:00:00 GMT
• timmerman traverse for lsc 2023 - timmermanreport.com Timmerman Report Fri, 09 Jun 2023 16:15:07 GMT
• merck's keytruda posts trial win in 'messy' early nsclc realm FiercePharma Sat, 03 Jun 2023 07:00:00 GMT
• we fact checked the pharmacy guild's claims about medicine shortages. here's what we found ABC News Thu, 25 May 2023 07:00:00 GMT
• podcast: asco23: relativity-047, checkmate-038, and other advances in immunotherapy ASCO Daily News Thu, 25 May 2023 07:00:00 GMT
• asco preview: merck's keytruda, novartis' kisqali face their ... FiercePharma Thu, 25 May 2023 07:00:00 GMT
• checkmate or stalemate? the global healthcare m&a chess game Data Driven Investor Wed, 24 May 2023 07:00:00 GMT
• chutes & ladders—gilead finds christi shaw replacement, taps roche exec to fly kite Fierce Biotech Fri, 19 May 2023 07:00:00 GMT
• nccn clinical practice guidelines in oncology 2023 updates The ASCO Post Fri, 19 May 2023 07:00:00 GMT
• regulatory tracker: ucb's zilbrysq picks up eu nod to treat ... FiercePharma Wed, 17 May 2023 15:16:51 GMT
• regulatory tracker: amid glp-1 probe, eu asks companies for more ... FiercePharma Wed, 17 May 2023 15:16:51 GMT
• cancer vaccines clinical trial pipeline analysis demonstrates 250+ key companies at the horizon expected to ... GlobeNewswire Mon, 15 May 2023 07:00:00 GMT
• one subcutaneous form goes, but the opdivo dream continues Evaluate Pharma Thu, 27 Apr 2023 07:00:00 GMT
• aacr: astrazeneca's imfinzi lung cancer data raise new questions FiercePharma Sun, 16 Apr 2023 07:00:00 GMT
• single-agent pembrolizumab may benefit patients with rare type of ... American Association for Cancer Research (AACR) Sun, 16 Apr 2023 07:00:00 GMT
• aacr 2023 – more hope for moderna’s neoantigen immunotherapy Evaluate Pharma Sun, 16 Apr 2023 07:00:00 GMT
• jason luke, md, on low-dose adjuvant ipilimumab plus nivolumab for advanced melanoma Medpage Today Thu, 13 Apr 2023 07:00:00 GMT
• q1 accepted ndas and sblas to keep a watchful eye on Dermatology Times Thu, 30 Mar 2023 07:00:00 GMT
• initial evidence for the efficacy of naporafenib in combination with ... ASCO Journals Wed, 22 Mar 2023 07:00:00 GMT
• extended follow-up supports first-line use of nivolumab plus ... The ASCO Post Fri, 10 Mar 2023 08:00:00 GMT
• astrazeneca touts 2 lung cancer wins as keytruda showdown looms FiercePharma Thu, 09 Mar 2023 08:00:00 GMT
• merck ends last keytruda trial in aggressive prostate cancer ... FiercePharma Tue, 28 Feb 2023 08:00:00 GMT
• skin cancer drugs global market research report 2023 with focus ... Yahoo Finance Tue, 28 Feb 2023 08:00:00 GMT
• merck targets bms' stomach cancer head start with keytruda win ... FiercePharma Thu, 16 Feb 2023 08:00:00 GMT
• opdivo® (nivolumab) in combination with cabometyx ... Bristol-Myers Squibb Mon, 13 Feb 2023 08:00:00 GMT
• are chemtrails being used to vaccinate australians secretly against covid-19? checkmate investigates ABC News Thu, 09 Feb 2023 08:00:00 GMT
• keytruda wins broad adjuvant nsclc nod to pressure tecentriq FiercePharma Fri, 27 Jan 2023 08:00:00 GMT
• multimodal sequencing achieves high-quality results from small ... Columbia University Tue, 24 Jan 2023 08:00:00 GMT
• multimodal sequencing achieves high-quality result | newswise Newswise Wed, 18 Jan 2023 08:00:00 GMT
• immunitas therapeutics announces first patient dosed in phase 1 ... PR Newswire Wed, 04 Jan 2023 08:00:00 GMT
• zielbio appoints alan bash ceo as company advances oncology therapeutics PR Newswire Tue, 03 Jan 2023 08:00:00 GMT
• 2022 turns out to be another unspectacular year for pharma and ... The Pharma Letter Mon, 02 Jan 2023 08:00:00 GMT
• immunotherapy and biomarker testing in recurrent and metastatic ... ASCO Journals Thu, 15 Dec 2022 08:00:00 GMT
• nivolumab plus cabozantinib with or without ipilimumab for ... ASCO Journals Tue, 13 Dec 2022 08:00:00 GMT
• nivolumab plus ipilimumab versus extreme regimen as first ... ASCO Journals Tue, 06 Dec 2022 08:00:00 GMT
• regeneron's libtayo posts lung cancer win with bristol's yervoy. but company won't seek approval FiercePharma Thu, 01 Dec 2022 08:00:00 GMT
• regeneron teams up with cytomx to develop dual-targeting cancer drugs BioPharma Dive Thu, 17 Nov 2022 08:00:00 GMT
• chutes & ladders—seagen finds new leader after 6-month vacancy Fierce Biotech Fri, 11 Nov 2022 08:00:00 GMT
• takeout premiums hold up, but that’s not the whole story Evaluate Pharma Wed, 09 Nov 2022 08:00:00 GMT
• fusion pharmaceuticals announces third quarter 2022 financial results and clinical program updates PR Newswire Tue, 08 Nov 2022 08:00:00 GMT
• 2022-11-08 | ndaq:fusn | press release | fusion pharmaceuticals inc Stockhouse Publishing Tue, 08 Nov 2022 08:00:00 GMT
• fusion pharmaceuticals appoints dmitri bobilev, m.d. as chief medical officer PR Newswire Mon, 07 Nov 2022 08:00:00 GMT
• scorpion therapeutics announces formation of world-class clinical scientific advisory board Business Wire Mon, 07 Nov 2022 08:00:00 GMT
• xoma reports third quarter 2022 financial results and highlights recent operational events GlobeNewswire Thu, 03 Nov 2022 07:00:00 GMT
• toll-like receptor agonist clinical trial pipeline analysis featuring 60+ key companies by delveinsight | Medgadget Thu, 20 Oct 2022 07:00:00 GMT
• five-year survival outcomes with nivolumab plus ipilimumab ... ASCO Journals Wed, 12 Oct 2022 07:00:00 GMT
• combination dabrafenib and trametinib versus combination nivolumab and ipilimumab for patients with advanced ... ASCO Journals Thu, 06 Oct 2022 18:37:38 GMT
• metastatic melanoma clinical trial pipeline analysis featuring 75+ key companies by delveinsight | Medgadget Thu, 06 Oct 2022 07:00:00 GMT
• induction exposure dose of ipilimumab and failure of adjuvant nivolumab plus ipilimumab in melanoma ASCO Journals Wed, 28 Sep 2022 05:41:22 GMT
• combination dabrafenib and trametinib versus combination nivolumab and ipilimumab for patients with advanced ... ASCO Journals Tue, 27 Sep 2022 07:00:00 GMT
• induction exposure dose of ipilimumab and failure of adjuvant nivolumab plus ipilimumab in melanoma ASCO Journals Mon, 26 Sep 2022 20:29:56 GMT
• biospace movers & shakers: sotio, voyager, nutcracker and more BioSpace Fri, 16 Sep 2022 07:00:00 GMT
• movers & shakers: sotio, voyager, nutcracker and more | biospace BioSpace Fri, 16 Sep 2022 07:00:00 GMT
• BioSpace Movers & Shakers: SOTIO, Voyager, Nutcracker and More BioSpace Thu, 15 Sep 2022 07:00:00 GMT
• rich insights into the robust metastatic melanoma clinical trials pipeline analysis featuring 75+ companies ... GlobeNewswire Thu, 18 Aug 2022 07:00:00 GMT
• if you invested $10,000 in regeneron pharmaceuticals 5 years ago, this is how much you would have today The Motley Fool Sat, 06 Aug 2022 07:00:00 GMT
• xoma reports second quarter 2022 financial results and highlights recent operational events GlobeNewswire Thu, 04 Aug 2022 07:00:00 GMT
• regeneron reports second quarter 2022 financial and operating ... PR Newswire Wed, 03 Aug 2022 07:00:00 GMT
• using circulating tumor dna in colorectal cancer: current and ... ASCO Journals Fri, 15 Jul 2022 07:00:00 GMT
• regeneron completes purchase of sanofi's stake in libtayo ... PR Newswire Fri, 01 Jul 2022 07:00:00 GMT
• prognosis of patients with primary melanoma stage i and ii according to american joint committee on cancer version ... ASCO Journals Thu, 16 Jun 2022 07:00:00 GMT
• Gilboa Therapeutics Appoints Barry Labinger as CEO to Develop Cell Therapy Platform Targeting Solid Tumors WebWire Tue, 14 Jun 2022 07:00:00 GMT
• regeneron to buy global license rights to sanofi's libtayo Pharmaceutical Technology Fri, 03 Jun 2022 07:00:00 GMT
• phase ii randomized study of ramucirumab and pembrolizumab ... ASCO Journals Fri, 03 Jun 2022 07:00:00 GMT
• Regeneron pays Sanofi $900M for full rights to cancer drug Libtayo as it looks to become a force in oncology Fierce Pharma Thu, 02 Jun 2022 07:00:00 GMT
• Regeneron is paying $900M for full rights to cancer drug partnered with Sanofi MedCity News Thu, 02 Jun 2022 07:00:00 GMT
• regeneron completes acquisition of checkmate pharmaceuticals PR Newswire Tue, 31 May 2022 07:00:00 GMT
• securities complaint says regeneron’s acquisition of checkmate pharmaceuticals lacks key disclosures Law Street Media Mon, 16 May 2022 07:00:00 GMT
• Update: Checkmate details bleak future if $250M Regeneron merger does not close Fierce Biotech Fri, 13 May 2022 07:00:00 GMT
• regeneron didn't want to 'bid against itself' in checkmate deal as five global pharmas declined to counteroffer Endpoints News Fri, 13 May 2022 07:00:00 GMT
• checkmate details troubled future if regeneron's $250m buy fails Fierce Biotech Fri, 13 May 2022 07:00:00 GMT
• checkmate pharmaceuticals announces first quarter 2022 financial results and provides business update Yahoo Finance Thu, 12 May 2022 07:00:00 GMT
• iowa medtech symposium features innovators, venture capitalists Corridor Business Tue, 10 May 2022 07:00:00 GMT
• pfizer’s biohaven deal may open an era of smarter pharma acquisitions Bloomberg Tue, 10 May 2022 07:00:00 GMT
• pfizer's biohaven deal may open an era of smarter pharma acquisitions Bloomberg Tue, 10 May 2022 07:00:00 GMT
• high-quality pharma stock captures powerful biotech mega trend Money and Markets Tue, 03 May 2022 07:00:00 GMT
• codiak appoints david mauro, m.d., ph.d., as chief medical officer GlobeNewswire Mon, 02 May 2022 07:00:00 GMT
• the ‘innovation gap’ haunts big pharma, and the race is on for the next blockbusters PharmaVoice Thu, 28 Apr 2022 07:00:00 GMT
• shareholder investigation: halper sadeh llp investigates cmpi, clbs, isle, aogo PR Newswire Thu, 28 Apr 2022 07:00:00 GMT
• rare poison pill strategy an oddity among premium price takeover bids flurry Baystreet.ca Tue, 26 Apr 2022 07:00:00 GMT
• regeneron buys art krieg’s biotech startup for a discount price, boosting i/o pipeline Endpoints News Fri, 22 Apr 2022 07:00:00 GMT
• stockwatch: checkmate shares quadruple on regeneron buyout Genetic Engineering & Biotechnology News Fri, 22 Apr 2022 07:00:00 GMT
• Regeneron Buys Checkmate, Bivalent Vaccine Progress, & a Fitting Acronym Timmerman Report Thu, 21 Apr 2022 07:00:00 GMT
• investor alert - the m&a class action firm is investigating the merger – acc, cmpi, extn AccessWire Thu, 21 Apr 2022 07:00:00 GMT
• Regeneron to Acquire Checkmate for $250M, Expanding Cancer I/O Pipeline Genetic Engineering and Biotechnology News Wed, 20 Apr 2022 07:00:00 GMT
• Regeneron signs agreement to acquire Checkmate for $250m Pharmaceutical Technology Wed, 20 Apr 2022 07:00:00 GMT
• Regeneron to Acquire Checkmate Pharmaceuticals in $250M Deal Contract Pharma Wed, 20 Apr 2022 07:00:00 GMT
• midday stock movers: plug power, wework, checkmate pharmaceuticals Investing.com Australia Wed, 20 Apr 2022 07:00:00 GMT
• regeneron to acquire checkmate pharmaceuticals for $250m Inside Precision Medicine Wed, 20 Apr 2022 07:00:00 GMT
• adaptimmune in two-day rally thanks to regeneron/checkmate deal; shares up 15% (adap) Seeking Alpha Wed, 20 Apr 2022 07:00:00 GMT
Checkmate Pharmaceuticals, Inc(NASDAQ:CMPI) 
Checkmate Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing novel therapeutics for the treatment of cancer. It develops CMP-001, which is in phase II clinical trial in combination with pembrolizumab to treat patients with PD-1 refractory melanom...
Website: http://www.checkmatepharma.com
Founded: 2015
Full Time Employees: 25 (May 2021)
CEO: Barry A. Labinger
Sector: Healthcare
Industry: Biotechnology
Share this website to your friends